Delivery Order SPE2DB20D1004-SPE2DB25FNKRM
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $7,621.24 for Zepbound 5 mg/0.5 mL pens on August 4, 2025, with completion scheduled for August 5, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. Zepbound (tirzepatide) is a GLP-1 receptor agonist indicated for weight management, representing the...
- The Defense Logistics Agency awarded a $21,713.14 delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pens. This competitively awarded, firm fixed-price contract was placed under a non-set-aside procurement and is scheduled for completion by September 5, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Zepbound (tirzepatide) 10 mg/0.5 mL in pen form, with a ceiling value of $3,762.89. The award, issued on August 28, 2025, with an ultimate completion date of August 29, 2025, utilizes firm fixed pricing under a non-competitive set-aside structure. Performance will occur at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a continuation of...
- The Defense Logistics Agency awarded a $2,045.91 delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pen injectors. This competitively awarded, non-set-aside contract is structured as a firm fixed price delivery order with an ultimate completion date of August 11, 2025, and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Zepbound is a diabetes and weight management medication, reflecting...
- The Defense Logistics Agency awarded a $1,906.45 delivery order to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 mL pen injectors on August 18, 2025. This non-competitive delivery order represents a firm fixed price transaction with a performance completion date of August 19, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $14,950.78 to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Zepbound (tirzepatide) 15 mg/0.5 mL pen injectors. This competitively awarded, firm fixed-price contract is scheduled for completion by July 24, 2025, with performance taking place at AmerisourceBergen's corporate offices in Conshohocken, Pennsylvania. The contract represents a single delivery order issued under a larger procurement vehicle and carries...
- The Defense Logistics Agency awarded a $7,993.05 firm fixed price delivery order to AmerisourceBergen Drug Corp for ZEPBOUND (tirzepatide) 5 mg/0.5 ml pen injections on August 18, 2025, with an ultimate completion date of August 19, 2025. This non-competitive delivery order represents a single-use purchase of the FDA-approved diabetes and weight management medication under the company's existing contract vehicle. The performance location is AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $35,643.13 to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 7.5 mg/0.5 mL pens on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitive, firm fixed-price delivery order carries no set-aside designation and will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a single delivery order under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at approximately $43.3K to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pens on July 25, 2025, with an ultimate completion date of July 28, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside contract and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract falls under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $4,888.38 delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Zepbound (tirzepatide) 12.5 mg/0.5 mL in pen form with an ultimate completion date of August 25, 2025. This competitive award, issued without set-aside designation, carries firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply contract vehicle with DLA. The product will be performed at the company's...
- SPE2DB20D1004Indefinite Delivery Contract
- SPE2DB20D1004-SPE2DB25FNKRMDelivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,232.80 on September 10, 2025, for the supply of Zepbound (tirzepatide) 12.5 mg/0.5 mL in pre-filled pen format. This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of September 11, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vendor agreement running through December 2026. The parent contract serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply pharmaceuticals and medical supplies to support military healthcare programs and other federal agencies including the Defense Health Agency and U.S. Coast Guard. Zepbound, a diabetes and weight management medication, falls within the broad therapeutic domains covered under the IDC, which encompasses specialty medications, brand-name and generic drugs, vaccines, and related medical supplies.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.2k | 9/10/25 |